A feasibility study on the development of Psorax35 as the first and only oral treatment for mild-to-moderate psoriasis with positive effects on co-morbidities.

Project Information

PsoraxPlan

Grant agreement ID: 877522

DOI 10.3030/877522

Project closed

EC signature date 26 July 2019

Start date 1 August 2019

End date 31 January 2020

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost € 71 429,00

EU contribution € 50 000,00

Coordinated by

ARCTIC NUTRITION AS
Norway